With an aging population, better rates of diagnosis, and an increase of central nervous system diseases after the age of 65, there is a mounting need to discover and develop more innovative and effective therapeutic treatments focused on the central nervous system.
Charles River offers a wide range of services supported by our scientific depth, unique technical capabilities, and experience in all the major neurodegenerative diseases and neurological indications, such as Alzheimer’s disease, Parkinson’s disease, chronic pain, epilepsy, Multiple Sclerosis, stroke, and more. From animal models of disease and preclinical testing to clinical trials, we have developed the tools to assist clients in shortening the development cycle of compounds with neurological implications.